Machine Learning

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

As community hubs face new threats, advanced AI surveillance offers powerful protection. But what are the costs and ethical lines for Canadian organizations?

Ontario's new FAST program speeds access to cancer drugs like Scemblix, challenging Canada's slow reimbursement system. Is this a new national blueprint?

Promising data for NuCana's NUC-7738 offers hope for tough-to-treat melanoma, but the biotech's financial health presents a critical hurdle.

Impressive new trial data for MDNA11 could disrupt the multi-billion dollar immunotherapy market, offering real hope where standard treatments now fail.

The ESA's new elite summit, iicon, replaces E3, targeting C-suites to leverage gaming tech across healthcare, finance, and media. What's at stake?

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

With $47.5M and a veteran CEO, PsiThera is using its advanced AI platform to develop oral medicines for diseases long-dominated by injectable biologics.

Herbalife's new podcast with Paralympian Palak Kohli reveals a deeper trend: how corporate content is fueling a new ecosystem for para-athletes in India.

Capital Power unveils a $3B deal with Apollo to buy U.S. gas plants while securing a major deal to power Alberta's AI boom, a bold dual strategy.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

An award-winning telecom platform reveals how AI-driven, unified journeys can transform customer experience. What can healthcare learn from this model?

A French cancer institute is the first in Europe to deploy a new radiotherapy system that promises not just better accuracy, but a more humane patient journey.

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

Denali Therapeutics raises $200M to advance its brain-penetrating drugs, betting big on its pipeline despite short-term market jitters.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

Beijing 101 blends TCM with high-tech devices for scalp care. We analyze the business strategy behind this fusion in a competitive wellness market.

A 1.01 Tbps cyberattack was just a skirmish in a wider war. See how advanced AI and massive defenses are the new front line against digital extortion.

Gossamer Bio's recent 200,000-share grant to a new hire is more than a welcome bonus; it's a strategic bet on its blockbuster drug candidate.

As EMEA faces a critical tech skills shortage, Skillsoft’s AWS award reveals a proven blueprint for building the cloud and AI workforce of the future.